GlobeNewswire: Beta Bionics Contains the last 10 of 10 releaseshttp://www.globenewswire.com/External?Length=42024-03-28T17:41:03ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2020/02/20/1987793/0/en/Beta-Bionics-Appoints-Martha-Aronson-and-Sean-Carney-to-Its-Board-as-Independent-Directors.html?f=22&fvtc=4&fvtv=48085Beta Bionics Appoints Martha Aronson and Sean Carney to Its Board as Independent Directors2020-02-20T13:00:00Z<![CDATA[WEST CONCORD, Mass., Feb. 20, 2020 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. — a medical technology company developing and aiming to commercialize the world’s first fully automated bionic pancreas system called the iLet® today announced that Martha G. Aronson and Sean D. Carney have been appointed to the Company’s Board of Directors effective immediately.]]>https://www.globenewswire.com/news-release/2019/12/10/1958317/0/en/Beta-Bionics-Receives-FDA-Breakthrough-Device-Designation-for-the-iLet-Bionic-Pancreas-System.html?f=22&fvtc=4&fvtv=48085Beta Bionics Receives FDA Breakthrough Device Designation for the iLet™ Bionic Pancreas System2019-12-10T07:00:00Z<![CDATA[BOSTON, Dec. 10, 2019 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. — a medical technology company developing and aiming to commercialize the world’s first fully automated bionic pancreas — today announced it has received Breakthrough Device designation from the U.S. Food and Drug Administration (FDA) for its investigational iLet Bionic Pancreas System.]]>https://www.globenewswire.com/news-release/2019/12/03/1955480/0/en/Encouraging-Results-of-Pilot-Study-Testing-Bionic-Pancreas-in-Cystic-Fibrosis-Related-Diabetes-Published-in-Journal-of-Cystic-Fibrosis.html?f=22&fvtc=4&fvtv=48085Encouraging Results of Pilot Study Testing Bionic Pancreas in Cystic Fibrosis-Related Diabetes Published in Journal of Cystic Fibrosis2019-12-03T13:00:00Z<![CDATA[BOSTON, Dec. 03, 2019 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. — a medical technology company developing and aiming to commercialize the world’s first fully automated bionic pancreas today announced that its bionic pancreas glucose control algorithms that use lifelong autonomous learning were deployed in a pilot study comparing usual care with automated insulin-only and bihormonal (insulin and glucagon) delivery in three patients with cystic fibrosis related diabetes (CFRD). Results of the study were published in the Journal of Cystic Fibrosis (J.S. Sherwood, R.Z. Jafri, C.A. Balliro, et al., Automated glycemic control with the bionic pancreas in cystic fibrosis-related diabetes: A pilot study, Journal of Cystic Fibrosis, https://doi.org/10.1016/j.jcf.2019.08.002).]]>https://www.globenewswire.com/news-release/2019/07/17/1883930/0/en/Beta-Bionics-and-ConvaTec-Announce-Partnership-to-Bring-Unomedical-Infusion-Set-Portfolio-to-the-iLet-Bionic-Pancreas-System.html?f=22&fvtc=4&fvtv=48085Beta Bionics and ConvaTec Announce Partnership to Bring Unomedical Infusion Set Portfolio to the iLet™ Bionic Pancreas System2019-07-17T12:00:00Z<![CDATA[BOSTON and READING, United Kingdom, July 17, 2019 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. — a medical technology company leveraging lifelong autonomous learning to develop and commercialize the world’s first fully automated bionic pancreas — and ConvaTec Group Plc (LSE: CTEC) — a leading global medical products and technologies company — today announced that ConvaTec’s Unomedical subsidiary and Beta Bionics have entered into a collaboration and development agreement that will make portions of Unomedical’s world class infusion sets available for use with the iLet Bionic Pancreas System.]]>https://www.globenewswire.com/news-release/2019/07/01/1876931/0/en/Beta-Bionics-Announces-Closing-of-a-63-Million-Series-B2-Financing-Bringing-the-Total-Series-B-and-B2-Financings-to-126-Million.html?f=22&fvtc=4&fvtv=48085Beta Bionics Announces Closing of a $63 Million Series B2 Financing, Bringing the Total Series B and B2 Financings to $126 Million2019-07-01T18:50:34Z<![CDATA[BOSTON, July 01, 2019 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. — a medical technology company leveraging lifelong autonomous learning to develop and commercialize the world’s first fully automated bionic pancreas — today announced that the company has completed a $63 million Series B2 equity financing. This follows six months after the final close of another $63 million equity financing and brings the total combined Series B and B2 financings to just over $126 million.]]>https://www.globenewswire.com/news-release/2019/01/08/1682457/0/en/Beta-Bionics-Announces-Final-Closing-of-Its-63-Million-Series-B-Financing.html?f=22&fvtc=4&fvtv=48085Beta Bionics Announces Final Closing of Its $63 Million Series B Financing2019-01-08T21:19:17Z<![CDATA[BOSTON, Jan. 08, 2019 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. – a medical technology company leveraging lifelong, machine-learning, artificial intelligence to develop and commercialize the world’s first autonomous bionic pancreas – today announced that the company has now completed its Series B equity financing, which has reached a total of $63 million.]]>https://www.globenewswire.com/news-release/2018/10/09/1618791/0/en/Beta-Bionics-Awarded-Up-to-2-Million-NIH-Small-Business-Innovation-Research-SBIR-Grant.html?f=22&fvtc=4&fvtv=48085Beta Bionics Awarded Up to $2 Million NIH Small Business Innovation Research (SBIR) Grant2018-10-09T16:46:47Z<![CDATA[BOSTON, Oct. 09, 2018 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. – a medical technology company leveraging lifelong machine learning and artificial intelligence to develop and commercialize the world’s first autonomous bionic pancreas – today announced that it has been awarded up to $2 million in the form of an SBIR grant (R44-DK120234) by the NIDDK, which is part of the U.S. National Institutes of Health (NIH).]]>https://www.globenewswire.com/news-release/2018/09/17/1571803/0/en/Beta-Bionics-Secures-an-Initial-50-Million-Series-B-Round.html?f=22&fvtc=4&fvtv=48085Beta Bionics Secures an Initial $50 Million Series B Round2018-09-17T13:16:44Z<![CDATA[BOSTON, Sept. 17, 2018 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. – a medical technology company leveraging lifelong machine learning, artificial intelligence to develop and commercialize the world’s first autonomous bionic pancreas – today announced that the company has so far raised $50m of a Series B equity financing. The round was led by Eventide Asset Management, LLC the advisor to Eventide Mutual Funds. Eventide was founded in 2008 with a vision to provide high performance, value-based investments that are socially responsible. RTW Investments, LP also participated, along with Series A investor, Novo Nordisk A/S. Strategic partner Zealand Pharma A/S, developer of a stable and pump compatible glucagon analog, called dasiglucagon, previously committed $5 million to the round. Funds will be used to support ongoing product development of the Beta Bionics commercial-generation bionic pancreas technology for use in its insulin-only, glucagon-only, and bihormonal configurations.]]>https://www.globenewswire.com/news-release/2018/07/12/1536480/0/en/Beta-Bionics-Announces-Start-of-Home-Use-Clinical-Trials-with-the-iLet-Bionic-Pancreas-System-and-Receives-IDE-Approval-from-the-FDA-to-Expand-its-Clinical-Trials-to-Include-the-Se.html?f=22&fvtc=4&fvtv=48085Beta Bionics Announces Start of Home-Use Clinical Trials with the iLet™ Bionic Pancreas System and Receives IDE Approval from the FDA to Expand its Clinical Trials to Include the Senseonics Eversense CGM Integrated into the iLet2018-07-12T12:00:00Z<![CDATA[BOSTON, July 12, 2018 (GLOBE NEWSWIRE) -- Beta Bionics, Inc., a medical technology company leveraging life-long, machine-learning, artificial intelligence to develop and commercialize the iLet Bionic Pancreas System — the world’s first fully autonomous bionic pancreas —announced today that the FDA has approved a supplement filed by Beta Bionics to its previously approved investigational device exemption (IDE) expanding ongoing home-use clinical trials testing its new integrated technology, which combines the iLet bionic pancreas and the Senseonics Eversense CGM.]]>https://www.globenewswire.com/news-release/2018/05/21/1509314/0/en/Beta-Bionics-Receives-IDE-Approval-from-the-FDA-to-Begin-a-Home-Use-Clinical-Trial-Testing-the-New-iLet-Bionic-Pancreas-System.html?f=22&fvtc=4&fvtv=48085Beta Bionics Receives IDE Approval from the FDA to Begin a Home-Use Clinical Trial Testing the New iLet™ Bionic Pancreas System2018-05-21T12:00:00Z<![CDATA[BOSTON, May 21, 2018 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. – a medical technology company leveraging machine learning artificial intelligence to develop and commercialize the world’s first autonomous bionic pancreas – today announced that it has received FDA approval to begin recruitment for home-use studies testing the insulin-only configuration of its iLet bionic pancreas system in a series of groundbreaking trials in adults and children with type 1 diabetes (T1D). Adults 18 years and older with T1D will be recruited through Massachusetts General Hospital and Stanford University, and children 6-17 years old with T1D will be recruited through Nemours Children’s Health System, the Barbara Davis Center for Diabetes at the University of Colorado, and Stanford University.]]>